NuCana Plc (NCNA)
1.385
0.00 (0.00%)
USD |
NASDAQ |
Sep 03, 10:08
NuCana Research and Development Expense (Annual) : 16.79M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 16.79M |
| December 31, 2024 | 23.02M |
| December 31, 2023 | 31.15M |
| December 31, 2022 | 44.87M |
| December 31, 2021 | 50.66M |
| December 31, 2020 | 33.21M |
| Date | Value |
|---|---|
| December 31, 2019 | 25.17M |
| December 31, 2018 | 22.46M |
| December 31, 2017 | 22.76M |
| December 31, 2016 | 10.64M |
| December 31, 2015 | 8.626M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Biodexa Pharmaceuticals Plc | 5.026M |
| Mereo BioPharma Group Plc | 17.81M |
| BioNTech SE | 2.376B |
| Silence Therapeutics Plc | 60.29M |
| Autolus Therapeutics Plc | 128.59M |